Simpact Ventures

⁣
FDA clearance #2 for Ligence! Automated LV strain now FDA-cleared. Supporting faster, more consistent echo care for patients. ❤️⁣
⁣
By automating LV Strain, is making a "premium" clinical metric accessible to every echo lab in the US, regardless of their volume or staffing levels. It’s no longer about whether a clinician has the time; it’s about the patient getting the best diagnostic data possible.⁣
⁣
Fantastic news! Congratulations! 👏 ⁣
⁣
Read more:

Ligence secures second FDA 510(k) clearance, adding fully automated Left Ventricular Strain analysis - Ligence Lithuania, April 14th, 2026 – Ligence announces it has received its second U.S. Food and Drug Administration (FDA) 510(k) clearance for the newest iteration of its AI-powered echocardiography software, Ligence Heart. Building on its initial clearance, the updated platform now features fully automa...

On February 19, we joined the Final Demo Day of the Kozminski Impact Booster at Akademia Leona Koźmińskiego - Kozminski University. Simpact Ventures took part as a strategic partner, with Krzysztof Grochowski representing our team.

Big congrats to all the startups who took the stage. 👏🏻
See you at the next edition.